DILIsym development expands the scope of the software (e.g., extension to other DILI mechanisms) and updates the software to include relevant newly published data. The DILI-sim Initiative approves the particular areas of development, ultimately shaping the focus areas where the DILIsym modeling software will be able to most immediately support drug development programs.

What’s new in DILIsym version X (DSX)?

DILIsym X is available in beta. DSX is our newest, most exciting release of DILIsym yet!  A sample of the enhancements include:

  • A complete software redesign that includes command line and graphical interface options and server/cloud computing capability (HPGL)
  • NO RELIANCE on MATLAB base or runtime
  • 4 NEW exemplar compounds included with varying clinical presentations:
    • PF-04895162 (Generaux 2019)
    • Efavirenz
    • Anastrozole
    • Tamoxifen
  • 2 NEW SimCohorts that include variability in susceptibility to liver injury and biomarker-related parameters (ALT and bilirubin)

Key features of the DILIsym modeling software

  • In vitro extrapolation to in vivo predictions (IVIVE) of drug-induced liver injury (DILI) hazard in multiple preclinical species and in humans
  • Predicted DILI hazard can be traced back to its mechanistic source(s)
  • Incorporates inter-individual physiological variability
  • Incorporates PK/PD variability
  • User-friendly GUI to specify in silico experiments and visualize results
  • Transparent design and parameterization
  • Inclusive incorporation of the available literature for mechanistic representation of the physiology
  • Regularly updated to include leading edge science
  • Developed and supported by scientific and technical teams
  • Consortium members guide the development of DILIsym and may share data to support model development and improve the collective understanding of DILI
  • Informs drug development decisions and risk mitigation strategies